Global Type 1 Diabetes (T1D) Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Global Type 1 Diabetes (T1D) Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

According to our (Global Info Research) latest study, the global Type 1 Diabetes (T1D) market size was valued at USD 1956.2 million in 2023 and is forecast to a readjusted size of USD 2644.8 million by 2030 with a CAGR of 4.4% during review period.

Type 1 diabetes (T1D) is an autoimmune disease that occurs when a person’s pancreas stops producing insulin, the hormone that controls blood-sugar levels. T1D develops when the insulin-producing pancreatic beta cells are mistakenly destroyed by the body’s immune system. The cause of this attack is still being researched, however scientists believe the cause may have genetic and environmental components.

According to the Global Use of Medicines 2023 released by IQVIA Institute, the global drug expenditure in 2022 was about US$1.48 trillion (excluding COVID vaccine and treatment-related expenses), and it is predicted to grow at a rate of 3%-6% in the next few years. In terms of drug expenditure, this number in China was about 166 billion dollars in 2022. It is expected that the expenditure on medicines will increase in the next few years. From the perspective of demand, the trend of population aging, the increase of residents’ wealth and the improvement of health awareness will drive the demand for medicines.

Global Use of Medicines 2023 shows that the U.S. market spent about US$ 62.9 billion on medicines in 2022 on a net ex-factory basis. Overall growth slows as the Inflation Reduction Act (IRA) spends US$64 billion to reduce prescription drug prices, and the adoption of new treatments is expected to increase over the next few years. Besides, ex-factory discounts and rebates in drug distribution, the impact of patent expiration, and generic or biosimilar competition will also affect the U.S. pharmaceutical market.

The Global Info Research report includes an overview of the development of the Type 1 Diabetes (T1D) industry chain, the market status of Children (Rapid Acting Insulin Analogs, Long Acting Insulin Analogs), Adults (Rapid Acting Insulin Analogs, Long Acting Insulin Analogs), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Type 1 Diabetes (T1D).

Regionally, the report analyzes the Type 1 Diabetes (T1D) markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Type 1 Diabetes (T1D) market, with robust domestic demand, supportive policies, and a strong manufacturing base.

Key Features:

The report presents comprehensive understanding of the Type 1 Diabetes (T1D) market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Type 1 Diabetes (T1D) industry.

The report involves analyzing the market at a macro level:

Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (K Units), revenue generated, and market share of different by Type (e.g., Rapid Acting Insulin Analogs, Long Acting Insulin Analogs).

Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Type 1 Diabetes (T1D) market.

Regional Analysis: The report involves examining the Type 1 Diabetes (T1D) market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.

Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Type 1 Diabetes (T1D) market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.

The report also involves a more granular approach to Type 1 Diabetes (T1D):

Company Analysis: Report covers individual Type 1 Diabetes (T1D) manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.

Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Type 1 Diabetes (T1D) This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Children, Adults).

Technology Analysis: Report covers specific technologies relevant to Type 1 Diabetes (T1D). It assesses the current state, advancements, and potential future developments in Type 1 Diabetes (T1D) areas.

Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Type 1 Diabetes (T1D) market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.

Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.

Market Segmentation

Type 1 Diabetes (T1D) market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.

Market segment by Type
Rapid Acting Insulin Analogs
Long Acting Insulin Analogs
Premix Insulin Analogs

Market segment by Application
Children
Adults

Major players covered
Novo Nordisk
Sanofi
Eli Lilly
Merck
Boehringer Ingelheim
Samsung Bioepis
Biocon
Astellas
Janssen
Bristol-Myers Squibb
Lexicon
Sanofi

Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Type 1 Diabetes (T1D) product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top manufacturers of Type 1 Diabetes (T1D), with price, sales, revenue and global market share of Type 1 Diabetes (T1D) from 2019 to 2024.

Chapter 3, the Type 1 Diabetes (T1D) competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Type 1 Diabetes (T1D) breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2019 to 2030.

Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2019 to 2030.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2023.and Type 1 Diabetes (T1D) market forecast, by regions, type and application, with sales and revenue, from 2025 to 2030.

Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.

Chapter 13, the key raw materials and key suppliers, and industry chain of Type 1 Diabetes (T1D).

Chapter 14 and 15, to describe Type 1 Diabetes (T1D) sales channel, distributors, customers, research findings and conclusion.